Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,884,709
  • Shares Outstanding, K 121,975
  • Annual Sales, $ 491,730 K
  • Annual Income, $ 163,890 K
  • EBIT $ 269 M
  • EBITDA $ 307 M
  • 60-Month Beta 0.70
  • Price/Sales 5.91
  • Price/Cash Flow 9.74
  • Price/Book 3.66

Options Overview Details

View History
  • Implied Volatility 47.44% ( +3.24%)
  • Historical Volatility 47.31%
  • IV Percentile 63%
  • IV Rank 42.86%
  • IV High 84.98% on 04/10/25
  • IV Low 19.27% on 06/17/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 146
  • Volume Avg (30-Day) 324
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 5,621
  • Open Int (30-Day) 3,833

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 0.53
  • Number of Estimates 3
  • High Estimate 0.58
  • Low Estimate 0.51
  • Prior Year 0.52
  • Growth Rate Est. (year over year) +1.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.80 +12.50%
on 05/08/25
25.01 -6.44%
on 05/02/25
+0.60 (+2.63%)
since 04/14/25
3-Month
20.23 +15.67%
on 03/11/25
26.16 -10.54%
on 03/24/25
+0.13 (+0.56%)
since 02/14/25
52-Week
14.75 +58.64%
on 06/26/24
26.16 -10.54%
on 03/24/25
+6.91 (+41.90%)
since 05/14/24

Most Recent Stories

More News
Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

CPRX : 23.40 (-1.06%)
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading...

AZN : 66.23 (-2.20%)
$SPX : 5,892.58 (+0.10%)
VEEV : 240.30 (-0.37%)
CPRX : 23.40 (-1.06%)
AMGN : 262.28 (-3.02%)
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

CPRX : 23.40 (-1.06%)
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today

The drugmaker confirmed there's a strong market for two of its treatments.

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

CPRX : 23.40 (-1.06%)
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

CPRX : 23.40 (-1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 24.68
2nd Resistance Point 24.37
1st Resistance Point 23.89
Last Price 23.40
1st Support Level 23.10
2nd Support Level 22.79
3rd Support Level 22.31

See More

52-Week High 26.16
Last Price 23.40
Fibonacci 61.8% 21.80
Fibonacci 50% 20.45
Fibonacci 38.2% 19.11
52-Week Low 14.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar